The Race for More Cells - Progress and Challenges in Maximizing Cell Densities

Scientific progress in the cell and gene therapy field will accelerate clinical cell therapy programs in the coming years. As cell therapy trials advance from pre-clinical research to late-stage trials, cell culture platforms will need to meet increasing demands for cell yield and high cell densities while maintaining product quality and minimizing operating costs. To meet demand, traditional production methods that rely on planar cell culture vessels will require improvements in scale-out output, which can be quite tedious as a manual process. The challenge, then, becomes establishing an adherent culture platform that can effectively scale from relatively small needs of pre-clinical studies through Phase I/II trials and into Phase III. As a result, the ability to scale-out will ease the transition from process development to manufacturing. This webinar provides potential solutions that may be considered to improve cell density and productivity in adherent cell culture in the areas of vaccines and viral vector production. It will also highlight the perfusion-based Corning® CellCube® system as a flexible, modular method for maximizing cell and high titer retroviral vector yields.